NTLA compared with CRSP: revenue, margins and what each company keeps, and the suppliers and customers both name

NTLAIntellia Therapeutics, Inc.

Mkt capRevenueRevenue

CRSPCRISPR Therapeutics AG

Mkt capRevenueRevenue

Compare

NTLAIntellia Therapeutics, Inc.

CRSPCRISPR Therapeutics AG

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

NTLA

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±14.2%▼−9.83%×0.69

Q2 FY26±12.8%▲+2.46%×0.20

May 11 '26±7.2%▲+2.34%×0.32

Q1 FY26±18.7%▲+6.41%×0.34

CRSP

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.7%0.00%×0.00

Q2 FY26±7.8%▲+7.06%×0.91

= impliedNTLA realized, solidCRSP realized, hatchedOne scale, both sides: full bar = 19%× = |realized| ÷ impliedSource: market data

Q1 FY26

±5.9%

▼−2.24%

×0.37

Feb 13 '26±3.6%▲+8.46%×2.36

NTLAIntellia Therapeutics, Inc.

11.35▲+2.23%· post 11.31

Mkt cap$1.6BRevenue$7MQ3 FY26Revenue$68MFY25

CRSPCRISPR Therapeutics AG

50.08▲+3.13%· post 50.00

ClosedNov 6 '26

Mkt cap$4.9BRevenue$13MQ3 FY26Revenue$4MFY25

Compare

ClosedNov 6 '26

NTLAIntellia Therapeutics, Inc.

CRSPCRISPR Therapeutics AG

11.35▲+2.23%post 11.31

Price

50.08▲+3.13%post 50.00

$1.6B

Mkt cap

$4.9B

Q3 FY26$7M

Revenue

$13MQ3 FY26

FY25$68M

Revenue

$4MFY25

NTLA11.35▲+2.23%vsCRSP50.08▲+3.13%ClosedNov 6 '26